Download PDF
Semin Liver Dis 2005; 25(3): 311-320
DOI: 10.1055/s-2005-916322
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Overlap Syndromes

Ulrich Beuers1 , 2 , Christian Rust2
  • 1Professor of Medicine, Department of Medicine II - Grosshadern, Ludwig Maximilians-University of Munich, Munich, Germany
  • 2Department of Medicine II - Grosshadern, Ludwig Maximilians-University of Munich, Munich, Germany
Further Information

Publication History

Publication Date:
06 September 2005 (online)

    Permissions and Reprints

ABSTRACT

In hepatology, the term overlap syndrome describes variant forms of the major hepatobiliary autoimmune diseases, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Patients with overlap syndromes present with both hepatitic and cholestatic biochemical and histological features of AIH, PBC, and/or PSC, and usually show a progressive course toward liver cirrhosis and liver failure without adequate treatment. AIH-PBC overlap syndromes have been reported in almost 10% of adults with AIH or PBC, whereas AIH-PSC overlap syndromes were found in 6 to 8% of children, adolescents, and young adults with AIH or PSC. A minority of patients may also show transition from stable PBC to AIH, AIH to PBC, or AIH to PSC, as documented by single case reports and small case series. Single cases of AIH and autoimmune cholangitis (antimitochondrial antibody-negative PBC) overlap have also been reported. Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes includes anticholestatic therapy with ursodeoxycholic acid and immunosuppressive therapy with corticosteroids and azathioprine. In end-stage disease, liver transplantation is the treatment of choice.

KEYWORDS

Autoimmune hepatitis - primary biliary cirrhosis - primary sclerosing cholangitis - cholestasis - hepatitis - autoimmune cholangitis

REFERENCES

  • 1 Czaja A J. The variant forms of autoimmune hepatitis.  Ann Intern Med. 1996;  125 588-598
    PubMedGoogle Scholar
  • 2 Heathcote E J. Overlap syndromes. In: Bircher J, Beuhamou JP, McIntyre N, Rizzetto M, Rodès J Oxford Textbook of Clinical Hepatology, Vol. 2. Oxford, United Kingdom; Oxford University Press 1999: 1135-1140
    Google Scholar
  • 3 Woodward J, Neuberger J. Autoimmune overlap syndromes.  Hepatology. 2001;  33 994-1002
    CrossrefPubMedGoogle Scholar
  • 4 Poupon R. Autoimmune overlapping syndromes.  Clin Liver Dis. 2003;  7 865-878
    CrossrefPubMedGoogle Scholar
  • 5 Colombato L A, Alvarez F, Cote J, Huet P M. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?.  Gastroenterology. 1994;  107 1839-1843
    PubMedGoogle Scholar
  • 6 Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.  Hepatology. 1998;  28 296-301
    CrossrefPubMedGoogle Scholar
  • 7 Gregorio G V, Portmann B, Karani J et al.. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.  Hepatology. 2001;  33 544-553
    CrossrefPubMedGoogle Scholar
  • 8 Abdo A A, Bain V G, Kichian K, Lee S S. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome.  Hepatology. 2002;  36 1393-1399
    CrossrefPubMedGoogle Scholar
  • 9 Beuers U. Hepatic overlap syndromes.  J Hepatol. 2005;  42(suppl 1) S93-S99
    CrossrefPubMedGoogle Scholar
  • 10 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31 929-938
    CrossrefPubMedGoogle Scholar
  • 11 Kanzler S, Weidemann C, Gerken G et al.. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis.  J Hepatol. 1999;  31 635-640
    CrossrefPubMedGoogle Scholar
  • 12 Terjung B, Bogsch F, Klein R et al.. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis.  Eur J Med Res. 2004;  9 439-448
    PubMedGoogle Scholar
  • 13 Prince M I, Chetwynd A, Craig W L, Metcalf J V, James O F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.  Gut. 2004;  53 865-870
    CrossrefPubMedGoogle Scholar
  • 14 Vierling J M. Primary biliary cirrhosis and autoimmune cholangiopathy.  Clin Liver Dis. 2004;  8 177-194
    CrossrefPubMedGoogle Scholar
  • 15 Heathcote E J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.  Hepatology. 2000;  31 1005-1013
    CrossrefPubMedGoogle Scholar
  • 16 Wiesner R H, LaRusso N F, Ludwig J, Dickson E R. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis.  Gastroenterology. 1985;  88 108-114
    PubMedGoogle Scholar
  • 17 Ludwig J, Colina F, Poterucha J J. Granulomas in primary sclerosing cholangitis.  Liver. 1995;  15 307-312
    PubMedGoogle Scholar
  • 18 Lee Y M, Kaplan M M. Primary sclerosing cholangitis.  N Engl J Med. 1995;  332 924-933
    CrossrefPubMedGoogle Scholar
  • 19 Heathcote J. Autoimmune cholangitis.  Gut. 1997;  40 440-442
    PubMedGoogle Scholar
  • 20 Brunner G, Klinge O. A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis) [in German].  Dtsch Med Wochenschr. 1987;  112 1454-1458
    PubMedGoogle Scholar
  • 21 Ben-Ari Z, Dhillon A P, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis.  Hepatology. 1993;  18 10-15
    CrossrefPubMedGoogle Scholar
  • 22 Sherlock S. Ludwig Symposium on biliary disorders. Autoimmune cholangitis: a unique entity?.  Mayo Clin Proc. 1998;  73 184-190
    PubMedGoogle Scholar
  • 23 Czaja A J, Carpenter H A, Santrach P J, Moore S B. Autoimmune cholangitis within the spectrum of autoimmune liver disease.  Hepatology. 2000;  31 1231-1238
    CrossrefPubMedGoogle Scholar
  • 24 Michieletti P, Wanless I R, Katz A et al.. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.  Gut. 1994;  35 260-265
    PubMedGoogle Scholar
  • 25 Taylor S L, Dean P J, Riely C A. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis.  Am J Surg Pathol. 1994;  18 91-99
    PubMedGoogle Scholar
  • 26 Goodman Z D, McNally P R, Davis D R, Ishak K G. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases.  Dig Dis Sci. 1995;  40 1232-1242
    PubMedGoogle Scholar
  • 27 Omagari K, Ikuno N, Matsuo I et al.. Autoimmune cholangitis syndrome with a bias towards primary biliary cirrhosis.  Pathology. 1996;  28 255-258
    PubMedGoogle Scholar
  • 28 Invernizzi P, Crosignani A, Battezzati P M et al.. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.  Hepatology. 1997;  25 1090-1095
    CrossrefPubMedGoogle Scholar
  • 29 Kinoshita H, Omagari K, Whittingham S et al.. Autoimmune cholangitis and primary biliary cirrhosis-an autoimmune enigma.  Liver. 1999;  19 122-128
    PubMedGoogle Scholar
  • 30 Neuberger J, Thomson R. PBC and AMA-what is the connection?.  Hepatology. 1999;  29 271-276
    CrossrefPubMedGoogle Scholar
  • 31 Miyakawa H, Tanaka A, Kikuchi K et al.. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens.  Hepatology. 2001;  34 243-248
    CrossrefPubMedGoogle Scholar
  • 32 Tsuneyama K, Van De Water J, Van Thiel D et al.. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis.  Hepatology. 1995;  22 1440-1446
    CrossrefPubMedGoogle Scholar
  • 33 Ikuno N, Scealy M, Davies J M et al.. A comparative study of antibody expressions in primary biliary cirrhosis and autoimmune cholangitis using phage display.  Hepatology. 2001;  34 478-486
    CrossrefPubMedGoogle Scholar
  • 34 Gordon S C, Quattrociocchi-Longe T M, Khan B A et al.. Antibodies to carbonic anhydrase in patients with immune cholangiopathies.  Gastroenterology. 1995;  108 1802-1809
    CrossrefPubMedGoogle Scholar
  • 35 Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases.  Am J Gastroenterol. 1998;  93 1334-1339
    CrossrefPubMedGoogle Scholar
  • 36 Comay D, Cauch-Dudek K, Hemphill D, Diamandis E, Wanless I, Heathcote E J. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?.  Dig Dis Sci. 2000;  45 2018-2021
    CrossrefPubMedGoogle Scholar
  • 37 Muratori L, Muratori P, Zauli D et al.. Antilactoferrin antibodies in autoimmune liver disease.  Clin Exp Immunol. 2001;  124 470-473
    CrossrefPubMedGoogle Scholar
  • 38 Lacerda M A, Ludwig J, Dickson E R, Jorgensen R A, Lindor K D. Antimitochondrial antibody-negative primary biliary cirrhosis.  Am J Gastroenterol. 1995;  90 247-249
    PubMedGoogle Scholar
  • 39 Kim W R, Poterucha J J, Jorgensen R A et al.. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.  Hepatology. 1997;  26 22-26
    PubMedGoogle Scholar
  • 40 James O F, Bhopal R, Howel D, Gray J, Burt A D, Metcalf J V. Primary biliary cirrhosis once rare, now common in the United Kingdom?.  Hepatology. 1999;  30 390-394
    CrossrefPubMedGoogle Scholar
  • 41 Kim W R, Lindor K D, Locke III G R et al.. Epidemiology and natural history of primary biliary cirrhosis in a US community.  Gastroenterology. 2000;  119 1631-1636
    CrossrefPubMedGoogle Scholar
  • 42 Boberg K M, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population.  Scand J Gastroenterol. 1998;  33 99-103
    CrossrefPubMedGoogle Scholar
  • 43 Geubel A P, Baggenstoss A H, Summerskill W H. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome.  Gastroenterology. 1976;  71 444-449
    PubMedGoogle Scholar
  • 44 Kloppel G, Seifert G, Lindner H, Dammermann R, Sack H J, Berg P A. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity.  Virchows Arch A Pathol Anat Histol. 1977;  373 143-160
    CrossrefPubMedGoogle Scholar
  • 45 Gheorghe L, Iacob S, Gheorghe C et al.. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease.  Eur J Gastroenterol Hepatol. 2004;  16 585-592
    PubMedGoogle Scholar
  • 46 Lohse A W, zum Buschenfelde K H, Franz B, Kanzler S, Gerken G, Dienes H P. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals.  Hepatology. 1999;  29 1078-1084
    CrossrefPubMedGoogle Scholar
  • 47 Yamamoto K, Terada R, Okamoto R et al.. A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease.  J Gastroenterol. 2003;  38 52-59
    CrossrefPubMedGoogle Scholar
  • 48 Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases.  Clin Rev Allergy Immunol. 2005;  28 115-133
    PubMedGoogle Scholar
  • 49 Kanzler S, Bozkurt S, Herkel J, Galle P R, Dienes H P, Lohse A W. Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome) [in German].  Dtsch Med Wochenschr. 2001;  126 450-456
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Beuers U. Overlap syndromes. In: Gershwin ME, Vierling, JM, Manns, MP Liver Immunology Philadelphia, PA; Hanley & Belfus 2003: 363-371
    Google Scholar
  • 51 Leuschner U. Autoimmunkrankheiten der Leber und Overlapsyndrome. Bremen, Germany; UNI-MED Verlag 2001
    Google Scholar
  • 52 Duclos-Vallee J C, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A.  Dig Dis Sci. 1995;  40 1069-1073
    CrossrefPubMedGoogle Scholar
  • 53 el-Shabrawi M, Wilkinson M L, Portmann B et al.. Primary sclerosing cholangitis in childhood.  Gastroenterology. 1987;  92 1226-1235
    PubMedGoogle Scholar
  • 54 Rabinovitz M, Demetris A J, Bou-Abboud C F, Van Thiel D H. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis.  Dig Dis Sci. 1992;  37 1606-1611
    CrossrefPubMedGoogle Scholar
  • 55 Lawrence S P, Sherman K E, Lawson J M, Goodman Z D. A 39 year old man with chronic hepatitis.  Semin Liver Dis. 1994;  14 97-105
    PubMedGoogle Scholar
  • 56 Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children.  J Pediatr. 1994;  124 49-56
    PubMedGoogle Scholar
  • 57 Wilschanski M, Chait P, Wade J A et al.. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis.  Hepatology. 1995;  22 1415-1422
    CrossrefPubMedGoogle Scholar
  • 58 Gohlke F, Lohse A W, Dienes H P et al.. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis.  J Hepatol. 1996;  24 699-705
    PubMedGoogle Scholar
  • 59 McNair A N, Moloney M, Portmann B C, Williams R, McFarlane I G. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases.  Am J Gastroenterol. 1998;  93 777-784
    CrossrefPubMedGoogle Scholar
  • 60 van Buuren H R, van Hoogstraten H JE, Terkivatan T, Schalm S W, Vleggaar F P. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis.  J Hepatol. 2000;  33 543-548
    CrossrefPubMedGoogle Scholar
  • 61 Kaya M, Angulo P, Lindor K D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system.  J Hepatol. 2000;  33 537-542
    CrossrefPubMedGoogle Scholar
  • 62 Chazouilleres O. Diagnosis of primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: to score or not to score?.  J Hepatol. 2000;  33 661-663
    CrossrefPubMedGoogle Scholar
  • 63 Beuers U, Spengler U, Kruis W et al.. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.  Hepatology. 1992;  16 707-714
    CrossrefPubMedGoogle Scholar
  • 64 Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis.  Scand J Gastroenterol Suppl. 1994;  204 59-61
    PubMedGoogle Scholar
  • 65 Lindor K D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.  N Engl J Med. 1997;  336 691-695
    CrossrefPubMedGoogle Scholar
  • 66 Mitchell S A, Bansi D S, Hunt N, Von Bergmann K, Fleming K A, Chapman R W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.  Gastroenterology. 2001;  121 900-907
    CrossrefPubMedGoogle Scholar
  • 67 Czaja A J, Carpenter H A. Autoimmune hepatitis with incidental histologic features of bile duct injury.  Hepatology. 2001;  34 659-665
    CrossrefPubMedGoogle Scholar
  • 68 Li C P, Tong M J, Hwang S J et al.. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid.  J Gastroenterol Hepatol. 2000;  15 95-98
    CrossrefPubMedGoogle Scholar
  • 69 Rubel L R, Seeff L B, Patel V. Primary biliary cirrhosis-primary sclerosing cholangitis overlap syndrome.  Arch Pathol Lab Med. 1984;  108 360-361
    PubMedGoogle Scholar
  • 70 Burak K W, Urbanski S J, Swain M G. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases.  Dig Dis Sci. 2001;  46 2043-2047
    CrossrefPubMedGoogle Scholar
  • 71 Zanger U M, Hauri H P, Loeper J, Homberg J C, Meyer U A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.  Proc Natl Acad Sci USA. 1988;  85 8256-8260
    PubMedGoogle Scholar
  • 72 Manns M P, Johnson E F, Griffin K J, Tan E M, Sullivan K F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.  J Clin Invest. 1989;  83 1066-1072
    PubMedGoogle Scholar
  • 73 Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.  J Clin Invest. 1991;  88 1370-1378
    PubMedGoogle Scholar
  • 74 Manns M P, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease.  Hepatology. 1997;  26 1054-1066
    CrossrefPubMedGoogle Scholar
  • 75 Lunel F, Abuaf N, Frangeul L et al.. Liver/kidney microsome antibody type 1 and hepatitis C virus infection.  Hepatology. 1992;  16 630-636
    PubMedGoogle Scholar
  • 76 Pawlotsky J M, Ben Yahia M, Andre C et al.. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study.  Hepatology. 1994;  19 841-848
    CrossrefPubMedGoogle Scholar
  • 77 Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection.  J Hepatol. 1999;  31 210-216
    PubMedGoogle Scholar

Ulrich BeuersM.D. 

Department of Medicine II-Grosshadern, Ludwig Maximilians-University of Munich

Marchioninistrasse 15, 81377 Munich, Germany

Email: Beuers@med.uni-muenchen.de